ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Oligopeptides/DNA Coacervate Droplets as Macromolecular Delivery Microcarriers.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Macromolecular therapeutics demonstrate significant advantages and potential for treating diverse diseases. However, their intrinsic physicochemical properties often hinder the selection of suitable carriers for efficient intracellular delivery. Here, we develop coacervates formed via liquid-liquid phase separation of oligopeptides and DNA as macromolecular carriers for cellular membrane translocation. These materials enable the efficient recruitment and release of biomacromolecules, including proteins and enzymes. Notably, our experimental data suggest that their uptake may not be entirely identical to classical endocytic pathways and instead involves cholesterol-dependent lipid raft interactions, indicating a mechanism that may be distinct from canonical clathrin-mediated endocytosis. Upon reaching the cytoplasm, the DNA component of the coacervates is degraded by intracellular DNA-processing enzymes, leading to coacervate disassembly and subsequent release of the therapeutic macromolecules. Together, these coacervates establish a generalizable platform for intracellular delivery of macromolecular therapeutics, integrating membrane translocation with programmable cytosolic release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.